nasopharyngeal carcinoma

Racing ahead of Merck and Innovent, Junshi declares PhIII success on cancer that won them 'breakthrough' status
Endpoints
Tue, 09/29/20 - 11:51 am
Junshi Biosciences
China
Merck
Innovent
nasopharyngeal carcinoma
toripalimab
China’s Junshi hits immuno-oncology milestone with breakthrough designation from FDA
MedCity News
Sat, 09/12/20 - 10:22 pm
China
Junshi Biosciences
immuno-oncology
toripalimab
nasopharyngeal carcinoma
FDA